Ongoing clinical investigations involving Ap-based therapeutics tested in these disorders are presented in Table 7: GLORIA for Olaptesed pegol in GBM; ApTOLL for anti-TLR4 DNA aptamer in stroke and MS; and NU 0129 for NA/Au NP targeting siRNA against BCL2L12 gene in recurrent GBM. This evidence concerns the gene TLR4 and glioblastoma.